VinFast VF 6, VF 7 Pre-booking To Begin From July 15, Check Delivery Details
The report says the brand will kickstart delivering the vehicle in 12 states. After seeing the response, it will expand the business strategy further.
The Vietnam-based four-wheeler electric wheeler maker VinFast has finally spread its roots in the Indian market. The company has introduce two EVs in the country named VF 6 and VF 7, and it is all set to start accepting the official pre-booking on July 15, 2025.
The report says the brand will kickstart delivering the vehicle in 12 states. After seeing the response, it will expand the business strategy, capturing the mass market in the segment. Those who are interested in purchasing the EVs can visit an authorised dealership.
Here's List Of Cities With Dealership
The company will have 32 dealerships across 27 cities, and aims to set up more than 34 dealerships by the end of CY 2025. The list includes Gurgaon, Delhi, Chennai, Noida, Hyderabad, Bengaluru, Jaipur, Pune, Kolkata, Ahmedabad, Cochin, Trivandrum, Bhubaneshwar, Chandigarh, Lucknow, Surat, Coimbatore, Visakhapatnam, Calicut, Vijayawada, Shimla, Jhansi, Agra, Gwalior, Baroda, Vapi and Goa.
Benefits
As per the details shared by the brand, all the touchpoints will have showrooms, complemented by service workshops and a spare parts department. This will allow the customers to have a seamless after-sales service. Apart from this, VinFast has tied up with Global Assure for 24/7 roadside assistance to make it more convenient so that they can go anywhere hassle-free.
view comments
First Published:
July 13, 2025, 15:48 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
25 minutes ago
- Indian Express
India begins crucial week-long trade negotiations with US
Days after US President Donald Trump announced fresh reciprocal tariff rates of up to 50 per cent for scores of countries, including the European Union, Canada, Brazil and ASEAN among others, Indian negotiators have begun a fresh round of talks in Washington to clinch a deal before August 1. 'India's aim is to sign a bilateral trade deal by the end of the year. The week-long negotiations have begun and the interim trade deal will depend on the willingness of both sides. If substantial agreement is reached, an interim agreement can be reached,' a senior government official said on Monday. Another official, seeking anonymity, said that India is in an advantageous position compared to other countries, particularly its Asian peers, and that the likelihood of India reaching a trade deal with the US is high. The ongoing round of negotiation comes less than 10 days after Indian officials, led by Special Secretary Rajesh Agarwal, returned from Washington on July 4. The Indian Express had reported that agriculture has been a major sticking point in the negotiations, particularly because India has adopted an unwavering stance on this sector. The US maintains that the August 1 cut-off date is not a new deadline but an outer limit for countries to 'speed things up', and that this strategy has helped bring trading partners such as the European Union on board. US Treasury Secretary Scott Bessent, when asked in a TV interview if there was a playbook for the US tariffs actions, said: 'The playbook is to apply maximum pressure. You know, we saw that the EU was very slow in coming to the table. Three weeks ago, on a Friday morning, President Trump threatened 50 per cent tariffs. And within a few hours, five of the European national leaders had called him. Ursula von der Leyen, the head of the EU, was on the phone and the EU is making very good progress. They were off to a slow start.' The threat from the Trump administration is that if the August 1 deadline is not adhered to, those countries go back to the April 2 tariff levels. Most of them are minor trading partners of the US and are likely outside America's 18 important trading relationships that account for 95 per cent of the country's trade deficit. Ravi Dutta Mishra is a Principal Correspondent with The Indian Express, covering policy issues related to trade, commerce, and banking. He has over five years of experience and has previously worked with Mint, CNBC-TV18, and other news outlets. ... Read More
Mint
31 minutes ago
- Mint
Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
Sun Pharma on Monday announced it has settled a patent row with American biopharma company Incyte Corporation over its hair-loss drug, paving the way for its launch in the US. The Mumbai-based drugmaker, embroiled in the lawsuit since last year, launched the specialty drug in the world's largest pharmaceutical market on Monday. Leqselvi (oral deuruxolitinib) is indicated for treatment of adults with severe alopecia areata. Under the terms of settlement and licensing agreement, the two companies will seek a dismissal of the pending litigation in the United States District Court for the District of New Jersey, the company said in a release. Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. Incyte has also granted a limited, non-exclusive licence to Sun to US patents no. 9,662,335 and other related patents. This licence covers oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, the company said. In return, Sun will pay Incyte an upfront amount, as well as ongoing royalty payments until expiry of the patents. The company did not reveal other specific terms of the settlement. In April 2025, Sun Pharma received a favourable ruling from the US Court of Appeals for the Federal Circuit, which vacated a preliminary injunction on Leqselvi's launch, lifting restrictions on the launch. Sun received approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator's approval, Incyte Corporation filed a patent infringement lawsuit against Sun Pharma, alleging that Leqselvi infringed upon its existing patents, delaying the launch. In November 2024, the US District Court of New Jersey granted a preliminary injunction, halting Leqselvi's launch in the US until the lawsuit was resolved. Sun Pharma on Monday announced the launch of Leqselvi in the US, in a separate release. The drug will be available for prescription in 8mg tablets in the country. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," said Richard Ascroft, CEO, Sun Pharma North America, in the release. Leqselvi demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks. Leqselvi is expected to be a $200 million opportunity for Sun Pharma in 3-4 years after launch, according to brokerage Elara Capital. Sun Pharma's shares ended 0.58% higher at ₹ 1,681.70 apiece on NSE on Monday.
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
The margin trap: Why innovation matters more than short-term profits
India needs to get on the innovation cycle - and everyone has a part to play. The government must provide basic funding and strengthen linkages between industry and academia Akash Prakash Listen to This Article One of the clear takeaways when speaking with senior people working with Apple is their disappointment at the lack of willingness among India Inc to step up and make the investments needed to bring the Apple ecosystem into India. While China is putting up obstacles, the profit focus of Indian entrepreneurs is also a stumbling block. Whether it is putting up the component supply chain or making large capital investments for display units, there is a lack of interest on the part of large Indian groups to commit capital. They cite the low margins on offer and the intense scrutiny
